Back to search results

Study of Omecamtiv Mecarbil for Chronic Heart Failure

This study is looking into whether an investigational drug called omecamtiv mecarbil can help people with chronic heart failure (when your heart can't pump enough blood) and a severely reduced ejection fraction (meaning your heart pumps out less blood than it should). The goal is to see if omecamtiv mecarbil can lower the risk of serious events like hospitalization, needing a heart transplant, or death related to heart failure. You might be able to join if you are between 18 and 85 years old, have had chronic heart failure for at least 3 months, and are currently taking oral loop diuretics. The study will measure how long it takes for participants to experience a cardiovascular (heart-related) death, a heart failure event, or need a heart assist device or transplant. The study is currently recruiting 1800 participants.

Study design
This is an interventional study where participants will be randomly assigned to receive either omecamtiv mecarbil or a placebo (an inactive pill). The study plans to enroll 1800 participants.
What's involved
Your participation in this study could last up to 3 years.
Compensation
Not stated in the trial record.
Follow-up
The study will follow participants from randomization until the last patient exits the study, estimated to be about 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06736574

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Recruiting
PHASE3Ages 18–85InterventionalTreatment
Cytokinetics
~1,800 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:Omecamtiv Mecarbil (OM)Placebo

At a glance

Recruiting sites
197 of 205 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to the first of event of CV death, HF event, LVAD implantation/cardiac transplantation, or stroke
Measured over From randomization to the first event of CV death or HF event, whichever occurs first, assessed until the last patient exits the study, estimated to last about 3 years

Conditions

Heart Failure
Heart Failure With Reduced Ejection Fraction

Explore related trials

Heart Failure

NCT06736574

Where you'd take part

This study runs at 205 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • A.O. Perugia - Ospedale S.Maria della Misericordia

    Perugia, Province of Perugia, Italyno site contact published

    Recruiting

  • Advanced Cardiovascular, LLC

    Alexander City, Alabamano site contact published

    Recruiting

  • Advanced Heart Care, LLC

    Bridgewater, New Jerseyno site contact published

    Recruiting

  • AdventHealth

    Orlando, Floridano site contact published

    Recruiting

  • Affiliated Hospital of Chifeng University

    Chifeng, Inner Mongolia, Chinano site contact published

    Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, Chinano site contact published

    Recruiting

  • AHEPA University General Hospital of Thessaloniki

    Thessaloniki, Thessaloniki, Greeceno site contact published

    Recruiting

  • AHMG Cardiology and Surgery

    Overland Park, Kansasno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Cytokinetics MD · STUDY_DIRECTOR · Cytokinetics

Who to contact

Cytokinetics MD
[email protected]
(650) 624-2929
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Are between ≥ 18 years and ≤ 85 years at the signing of informed consent
Have a history of chronic HFrEF, defined as requiring treatment for HF for a minimum of 3 months prior to screening
Are receiving oral loop diuretics on a regular schedule
Patients without AFF on screening ECG:
LVEF \< 30% within 6 months of screening
Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 1000 pg/mL (BNP ≥ 300 pg/mL)
Patients with AFF on screening ECG:
LVEF \< 25% within 6 months of screening
Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 3000 pg/mL (BNP ≥ 900 pg/mL)
Not currently taking digoxin
Meet one of the following criteria for a recent HF event:
Are currently hospitalized with the primary reason of HF
Had an HF event (as defined in the primary endpoint) within 12 months prior to screening. For the purposes of a qualifying HF event, subcutaneous furosemide will be treated as equivalent to intravenous furosemide Or
Had outpatient escalation of oral diuretics due to worsening signs and symptoms of heart failure plus one of two additional criteria sustained for at least 1 week: (1) at least 50% or 1.5-fold increase in daily loop-diuretic-equivalent dose; (2) the addition of a new diuretic class to a loop diuretic.
Are established on regional standard-of-care HF therapies for at least 30 days prior to screening
Systolic blood pressure ≤ 140 mmHg

Exclusion

Have AFF on the screening ECG and are currently taking digoxin
Have had any event or procedure that may have resulted in a change in ejection fraction, including, but not limited to, acute coronary syndrome and/or any coronary revascularization, cardiac surgery, valve surgery, any coronary revascularization, and/or cardiac resynchronization, or cardiac contractility modulation therapy within 3 months of screening
Are admitted to a long-term care facility or hospice
Have a projected survival of \< 12 months due to non-cardiovascular causes based on clinical judgment
Are receiving intravenous inotropes or intravenous vasopressors ≤ 3 days prior to screening
Are receiving mechanical hemodynamic support or mechanical ventilation ≤ 7 days prior to screening
Are receiving intravenous diuretics, intravenous vasodilators, or supplemental oxygen therapy ≤ 12 hours prior to screening (except for nocturnal supplemental oxygen for sleep apnea or heart failure)
Have an estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73m2 or receiving dialysis at screening
Have previously had a solid organ transplant
Are receiving treatment in another investigational device or drug study or are within 30 days of ending such investigational treatment at screening
Have received omecamtiv mecarbil in a previous clinical trial
Are pregnant or planning pregnancy during the study period, or planning to breastfeed during treatment with IP or within 5 days after the end of treatment with IP
Have primary infiltrative cardiomyopathy (e.g. cardiac amyloidosis) or severe stenotic valvular disease

What this trial measures

  • Time to the first of event of CV death, HF event, LVAD implantation/cardiac transplantation, or strokeFrom randomization to the first event of CV death or HF event, whichever occurs first, assessed until the last patient exits the study, estimated to last about 3 years

    Efficacy of omecamtiv mecarbil compared with placebo on the risk of HF outcomes in patients with symptomatic HFrEF and severely reduced ejection fraction in the setting of guideline-directed medical therapy per local standard of care.